Lertdetkajorn Khemaporn, Cobb Crystal, Kapolka Rebecca J, Hunt William R, Tangpricha Vin
Division of Endocrinology, Metabolism, and Lipids, Emory University School of Medicine, Atlanta, Georgia.
Division of Pulmonary, Allergy, Critical Care and Sleep, Emory University School of Medicine, Atlanta, Georgia.
AACE Clin Case Rep. 2024 Oct 4;11(1):32-35. doi: 10.1016/j.aace.2024.09.008. eCollection 2025 Jan-Feb.
BACKGROUND/OBJECTIVE: Men with cystic fibrosis (CF) have a high prevalence of low testosterone levels. A recent retrospective study demonstrated a quarter of a cohort of men with CF had serum testosterone levels below 300 ng/dL. The evaluation of hypogonadism is of increasing clinical importance in order to prevent unfavorable outcomes. Herein we present a 31-year-old man with CF and a relatively low serum testosterone value who was found to have an additional unsuspected cause of male hypogonadism.
The patient was a 31-year-old man with history of CF who was referred to endocrinology clinic for the evaluation of hypogonadism. Serum testing revealed a total testosterone of 175 ng/mL (296-1377), luteinizing hormone 2.8 mIU/mL (1.2-8.6), and a prolactin of 341 ng/mL (3-13). A brain magnetic resonance imaging was obtained, which revealed a 1 cm hypoenhancing left sellar lesion. He was started on cabergoline. His testosterone increased to 707 ng/dL after a year on cabergoline treatment. His prolactin decreased to 12 ng/mL after a year of treatment. The pituitary adenoma decreased 50% in size 2 years after cabergoline was initiated.
The most common etiologies of CF are recurrent infections, chronic inflammation, and glucocorticoid administration, which lead to both hypothalamic-pituitary dysregulation and primary hypogonadism. However, other less common causes of hypogonadism can also be found in CF.
We suggest that all men with cystic fibrosis found to have hypogonadism undergo additional evaluation for causes of hypogonadism prior to treatment with testosterone.
背景/目的:患有囊性纤维化(CF)的男性中,睾酮水平低的患病率很高。最近一项回顾性研究表明,一组CF男性中有四分之一的血清睾酮水平低于300 ng/dL。性腺功能减退的评估在预防不良后果方面的临床重要性日益增加。在此,我们报告一名31岁患有CF且血清睾酮值相对较低的男性,他被发现患有另一种未被怀疑的男性性腺功能减退病因。
该患者为一名31岁有CF病史的男性,因性腺功能减退被转诊至内分泌科门诊。血清检测显示总睾酮为175 ng/mL(296 - 1377),促黄体生成素为2.8 mIU/mL(1.2 - 8.6),催乳素为341 ng/mL(3 - 13)。进行了脑部磁共振成像检查,发现左侧蝶鞍区有一个1 cm的强化减弱病变。他开始使用卡麦角林治疗。使用卡麦角林治疗一年后,他的睾酮水平升至707 ng/dL。治疗一年后,他的催乳素降至12 ng/mL。开始使用卡麦角林两年后,垂体腺瘤大小缩小了50%。
CF最常见的病因是反复感染、慢性炎症和糖皮质激素的使用,这些会导致下丘脑 - 垂体调节失调和原发性性腺功能减退。然而,在CF患者中也可能发现其他不太常见的性腺功能减退病因。
我们建议,所有被发现患有性腺功能减退的囊性纤维化男性在接受睾酮治疗之前,应对性腺功能减退的病因进行进一步评估。